Cytoreductive RC Aids Survival of Metastatic Bladder Cancer Patients
Patients who underwent debulking had significantly longer overall survival compared with those who did not (median 15.7 vs 10 months).
AUA 2016 Bladder/Kidney Cancer
Survival Advantage Confirmed for Nephrectomy in mRCC
About 25% of patients who present with metastatic renal cancer will undergo nephrectomy after diagnosis.
Cytoreductive Nephrectomy Benefits Select mRCC Patients Taking TT
Among patients treated with targeted therapy, overall survival was 17.1 months for CN recipients vs 7.7 months for those without CN.
Neoadjuvant Chemo Rarely Used in Upper Tract Urothelial Cancer
Therapy used in less than 5% of cases, even in those with higher clinical stage.
Bladder Preservation Therapy for MIBC Predicts Worse Survival
Mortality risk decreases with increasingly stringent BPT compared with radical cystectomy.
More mRCC Patients Receiving Treatment
Cytoreductive nephrectomy (CN) use remained stable in the targeted therapy era, but more patients are receiving a combination of CN and systemic therapy.
Key Micronutrients Lacking in Black Bladder Cancer Survivors’ Diets
African American survivors had lower intakes of 8 select micronutrients, such as folate, compared with Caucasian survivors.
Bladder Cancer Risk Higher Following Prostate Radiotherapy
The increased risk occurs more than 10 years after treatment and most pronounced in men who undergo brachytherapy.
Gender Differences Found in Bladder Cancer Treatment, Survival
Cancer-specific survival at 5 years was 76.9% for men and 71.5% for women.
Partial Nephrectomy Feasible for T3a Renal Cell Carcinoma
Study shows no meaningful differences between partial and radical nephrectomy in 5-year rates of local recurrence or cancer-related death.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in AUA 2016 Bladder/Kidney Cancer
Loading... 
Loading...